KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Payables (2016 - 2025)

Merck (MRK) has disclosed Payables for 17 consecutive years, with $6.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Payables rose 6.18% to $6.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $6.5 billion, a 6.18% increase, with the full-year FY2025 number at $6.5 billion, up 6.18% from a year prior.
  • Payables was $6.5 billion for Q4 2025 at Merck, up from $6.2 billion in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.5 billion in Q4 2025 to a low of $5.0 billion in Q3 2021.
  • A 5-year average of $5.7 billion and a median of $5.6 billion in 2023 define the central range for Payables.
  • Peak YoY movement for Payables: dropped 5.56% in 2022, then grew 11.15% in 2025.
  • Merck's Payables stood at $6.4 billion in 2021, then fell by 3.59% to $6.1 billion in 2022, then decreased by 3.92% to $5.9 billion in 2023, then grew by 4.33% to $6.2 billion in 2024, then grew by 6.18% to $6.5 billion in 2025.
  • Per Business Quant, the three most recent readings for MRK's Payables are $6.5 billion (Q4 2025), $6.2 billion (Q3 2025), and $5.9 billion (Q2 2025).